17 active not recruiting, 9 recruiting, 6 completed, 5 withdrawn. 16 Phase 1, 8 Phase 2, 6 Early Phase 1, 5 Not applicable, 2 Phase 3.
Follow this condition Literature Review of Stage IV Ovarian Cancer AJCC v8 trials Research Report on Stage IV Ovarian Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer Behavioral Intervention, Educational Intervention, Internet-Based Intervention - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Not applicable | Withdrawn | City of Hope Medical Center | 2026-07-16 | 2026-02-04 | |
| Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy Biospecimen Collection, Placebo Administration, Probiotic - Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma | Early Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 161 | 2026-03-06 | 2026-08-17 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study Behavioral Intervention, Best Practice, Biospecimen Collection - Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Not applicable | Recruiting | Roswell Park Cancer Institute | 120 | 2025-06-04 | 2026-01-06 |
| e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study Discussion, Informational Intervention, Media Intervention - Malignant Female Reproductive System Neoplasm, Stage III Cervical Cancer AJCC v8 | Not applicable | Active not recruiting | City of Hope Medical Center | 23 | 2024-07-19 | 2026-01-28 |
| Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Alpha-type-1 Polarized Dendritic Cells, Autologous Natural Killer Cell-like CTLs - Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8 | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2023-12-15 | 2023-11-22 | |
| Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial Binimetinib, Biopsy Procedure, Biospecimen Collection - Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 199 | 2023-12-13 | 2026-08-21 |
| ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer Wee1 Inhibitor ZN-c3 - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-07-30 | 2023-05-06 | |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Biopsy, Pegylated SN-38 Conjugate PLX038, Computed Tomography - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 20 | 2022-09-14 | 2026-07-16 |
| Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer Biopsy Procedure, Carboplatin, Ipatasertib - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 25 | 2022-09-08 | 2026-09-22 |
| Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer Carboplatin, Cisplatin, Cytoreductive Surgery - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Early Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 35 | 2022-06-13 | 2026-08-17 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer Dostarlimab, Niraparib, Biopsy - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Active not recruiting | University of Washington | 18 | 2021-10-18 | 2026-08-20 |
| Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Behavioral Counseling, Nutritional Supplement Drink, Physical Activity - Advanced Ovarian Carcinoma, Stage IIIC Fallopian Tube Cancer AJCC v8 | Not applicable | Completed | Mayo Clinic | 90 | 2021-10-05 | 2025-08-08 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel - Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2021-09-30 | 2026-10-06 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Cisplatin, Elimusertib, Gemcitabine Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2021-08-25 | 2026-07-31 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
Showing 20 of 40. Sign in to see all of them.
Ovarian Neoplasms (40) · Fallopian Tube Neoplasms (20) · Pancreatic Neoplasms (9) · Prostatic Neoplasms (9) · Breast Neoplasms (7) · Colorectal Neoplasms (7) · Neoplasm Metastasis (7) · Endometrial Neoplasms (6) · Lung Neoplasms (6) · Uterine Cervical Neoplasms (6) · Melanoma (5) · Triple Negative Breast Neoplasms (5) · Carcinoma, Renal Cell (4) · Carcinoma, Non-Small-Cell Lung (3) · Stomach Neoplasms (3)
Adnexal Diseases (40) · Endocrine Gland Neoplasms (40) · Endocrine System Diseases (40) · Female Urogenital Diseases (40) · Female Urogenital Diseases and Pregnancy Complications (40) · Genital Diseases (40) · Genital Diseases, Female (40) · Gonadal Disorders (40) · Neoplasms by Site (40) · Urogenital Diseases (40) · Genital Neoplasms, Female (39) · Ovarian Diseases (39) · Neoplasms (38) · Urogenital Neoplasms (38) · Fallopian Tube Diseases (20)
Specimen Handling (15) · Biopsy (11) · Magnetic Resonance Spectroscopy (6) · Taxes (6) · Paclitaxel (5) · Carboplatin (4) · Gemcitabine (4) · 1,2-diaminocyclohexaneplatinum II citrate (3) · Behavior Therapy (3) · Cisplatin (3) · Disulfides (3) · Immunoglobulin G (3) · Letrozole (3) · Platinum (3) · X-Rays (3)
National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (7) · City of Hope Medical Center (4) · Mayo Clinic (3) · OHSU Knight Cancer Institute (3) · Roswell Park Cancer Institute (3) · Ohio State University Comprehensive Cancer Center (2) · University of Washington (2) · Massachusetts General Hospital (1) · NRG Oncology (1) · Northwestern University (1) · Pamela Munster (1) · Precigen, Inc (1) · Rutgers, The State University of New Jersey (1) · Wake Forest University Health Sciences (1)
United States (37) · Canada (4) · Puerto Rico (4) · Ireland (1) · Italy (1) · Mexico (1) · Netherlands (1) · Peru (1) · South Korea (1)
Anne Reb (2) · A P Chen (1) · Amanda N Fader (1) · Amanika A. Kumar, MD (1) · Amir A Jazaeri (1) · Amy R. Lankford, PhD (1) · Andrea E. Wahner Hendrickson, M.D. (1) · Apostolia M Tsimberidou (1) · Barbara S. Norquist (1) · Charles D Lopez, MD, PhD (1) · Christos Patriotis, PhD (1) · Devalingam Mahalingam (1) · Elizabeth M. Swisher (1) · Emese Zsiros (1) · Emese Zsiros, MD, PhD (1)
PMID 35264434, PMID 38176019, PMID 38236249, PMID 38471508, PMID 39570589, PMID 40058134, PMID 42847673
P30CA033572 (4), P50CA159981 (2), U10CA180868 (2), UM1CA186709 (2), P30CA012197 (1), P30CA016056 (1), P30CA060553 (1), P30CA072720 (1), P50CA136393 (1), R01CA164333 (1), R21CA293326 (1), U01CA062490 (1), U01CA152990 (1), U10CA180821 (1), U2CCA271871 (1)